Glaxo Wellcome
Closed portfolio snapshot
According to ClinicalTrials.gov-derived indexes, Glaxo Wellcome sits in the top decile of US sponsors by registered trial count (#318 of 15,742 sponsors by registered trial count).
Glaxo Wellcome: 65 sponsored US clinical trials, none currently recruiting.
Glaxo Wellcome sponsors 65 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 65 completed. 17 of these trials are in Phase 3-4 (later-stage) and 18 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is HIV Infections, with 18 trials.
Top-decile sponsor footprint
Glaxo Wellcome ranks in the top decile of sponsors by registered trial count (#318 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
65 of 65 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (100.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
65 total, page 1 of 2
A Study of Increased Lactic Acid and Abnormal Fat Distribution in HIV-Positive Patients
NCT00005764
A Study of the Safety and Effectiveness of Combination Anti-HIV Therapy in HIV-Infected Adults
NCT00004585
A Comparison of Three Anti-HIV Drug Combinations in HIV-Infected Patients
NCT00005106
Safety and Effectiveness of Lamivudine When Given Once a Day Versus Twice a Day in Combination With Other Anti-HIV Drugs in HIV-Infected Adults Who Have Never Received Anti-HIV Drugs
NCT00004852
Safety and Effectiveness of a Combination Anti-HIV Drug Treatment
NCT00005018
A Study to Compare the Safety and Effectiveness of Two Dosing Schedules of Lamivudine in Combination With Two Other Anti-HIV Drugs
NCT00002442
A Study of the Effects of Amprenavir, a Protease Inhibitor, on Carbohydrate and Fat Metabolism in HIV-Infected Patients
NCT00002245
A Study to Compare Two Anti-HIV Drug Combinations That Include Amprenavir in HIV-Infected Patients Who Have Failed Anti-HIV Drug Combinations That Did Not Include Amprenavir
NCT00002423
A Comparison of Two Multi-Drug Therapies in HIV-Infected Patients Who Have Never Received Anti-HIV Treatment
NCT00002216
A Study of 141W94 in Combination With Other Anti-HIV Drugs
NCT00002372
The Safety and Effectiveness of Zidovudine Plus Acyclovir in Patients With Early HIV Infection
NCT00002290
Trial of an Alternative Dosing Regimen of Oral Retrovir in Patients With AIDS or Advanced ARC
NCT00002020
The Efficacy and Safety of Retrovir in Patients Infected With HIV Who Are Asymptomatic (CDC Group II) or Have Persistent Generalized Lymphadenopathy (CDC Group III)
NCT00002048
Safety and Effectiveness of Giving Two Nucleoside Reverse Transcriptase Inhibitors Alone or in Combination With 141W94 to HIV-Infected Children Who Have Never Received Protease Inhibitors
NCT00002193
An Open-Label Study to Evaluate the Efficacy and Safety of Amprenavir (141W94) and Abacavir Combination Therapy in Protease Inhibitor Experienced Subjects With HIV-1 Infection Who Are Failing Their Current Antiretroviral Treatment Regimen
NCT00002205
A Dose-Frequency Trial of Oral Retrovir in Patients With AIDS or Severe ARC
NCT00002046
A Phase II Open Randomized Comparison of 566C80 and Pentamidine Isethionate for the Treatment of Pneumocystis Carinii Pneumonia in AIDS Patients Who Are Intolerant of Trimethoprim / Sulfamethoxazole
NCT00001996
A Phase I Trial to Evaluate the Safety, Pharmacokinetics and Antiviral Activity of 141W94 After Multiple Dosing in Patients With HIV Infection
NCT00002183
A Study of Azidothymidine (AZT) in the Treatment of HIV Infection in Patients Receiving a Bone Marrow Transplant
NCT00002284
A Study of Retrovir in the Treatment of Psoriasis in HIV-Positive Patients
NCT00002286
Treatment of AIDS and AIDS Related Complex. Part-1- Treatment of Patients With ARC (AZT Vs. Placebo)
NCT00002063
The Safety and Effectiveness of Lamivudine Plus Zidovudine, Used With and Without 1592U89, in HIV-1 Infected Patients Who Have Never Taken Anti-HIV Drugs
NCT00002389
A Comparative Trial of Valacyclovir Hydrochloride ( 256U87 ) and Acyclovir for the Suppression of Anogenital Herpes Infections in HIV-Infected Patients
NCT00002084
A Prospective Double-Blind Study of Retrovir in Early HIV Infection
NCT00002045
A Randomized Trial to Evaluate the Safety and Efficacy of Combination Therapy With Retrovir ( AZT ) and HIVID ( ddC ) Versus Retrovir, HIVID, and Wellferon ( Interferon Alfa-n1 ) for the Treatment of HIV Infection
NCT00002086
A Study of 1592U89 in Combination With Protease Inhibitors in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs
NCT00002440
A Study of Two Anti-HIV Drug Combinations
NCT00002203
A Study of Amprenavir in HIV-Infected Patients
NCT00002405
A Study of Retrovir and Epivir Alone or in Combination With 141W94 in HIV-Infected Patients
NCT00002195
The Safety and Effectiveness of 1592U89 Plus 141W94 Plus DMP 266 in Patients With HIV Who Developed a Resistance to Protease Inhibitors
NCT00002213
A Comparison of 882C87 Versus Acyclovir in the Treatment of Herpes Zoster in Patients With Weakened Immune Systems
NCT00002315
A Study of 1592U89 Combined With Other Anti-HIV Drugs in Patients Who Have Taken Anti-HIV Drugs
NCT00002364
The Safety and Effectiveness of Three Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Taken AZT
NCT00002436
3TC (Lamivudine; GR109714X) Open-Label Program
NCT00002108
The Safety and Effectiveness of Retrovir in HIV-Infected Patients Who Have Problems Related to the Nervous System
NCT00002288
A Comparison of Lamivudine and Zidovudine, Used Alone and Together, in HIV-Infected Patients Who Have Not Used Zidovudine in the Past
NCT00002320
A Study of 1592U89 and Ethanol When Given Together to HIV-Infected Patients
NCT00002198
A Study of a Combination of Four Drugs in Patients With Recent HIV Infection
NCT00002233
An Open-Label, Uncontrolled Clinical Trial of Oral 566C80 for the Treatment of Patients With Severe PCP Who Are Intolerant and/or Unresponsive to Therapy With Trimethoprim/Sulfamethoxazole and Parenteral Pentamidine
NCT00001990
A Study of Combivir Plus Abacavir Plus 141W94 in Patients Who Previously Have Used Anti-HIV Drugs
NCT00002217
A Phase I Study to Evaluate the Pharmacokinetics, Safety and Antiviral Effects of Concurrent Administration of Zidovudine (AZT) and 2'3'-Dideoxyinosine (ddI) in Patients With Human Immunodeficiency Virus (HIV)
NCT00002014
The Safety and Effectiveness of Zidovudine Plus Lamivudine, Used With and Without 1592U89, in HIV-1 Infected Children Who Have Taken Anti-HIV-1 Drugs
NCT00002391
A Pilot Study of 566C80 for the Salvage Treatment of Toxoplasmic Encephalitis in Patients Infected With the Human Immunodeficiency Virus (HIV) Who Have Failed or Are Intolerant of Pyrimethamine-Sulfadiazine
NCT00001994
The Safety and Effectiveness of Different Dose Levels of 1263W94 in the Treatment of Cytomegalovirus (CMV) of the Eyes in HIV-Infected Patients
NCT00002373
A Study of 1592U89 in HIV-Infected Patients
NCT00002388
A Pilot Study To Evaluate the Effect of Retrovir (Zidovudine: AZT) in the Treatment of Human Immunodeficiency Virus (HIV) Associated Dementia and Neuromuscular Diseases
NCT00002044
A Study of Retrovir in the Prevention of HIV Infection in Health Care Workers Accidentally Exposed to the Virus
NCT00002287
A Study of Zidovudine and T Lymphocyte Transfer in the Treatment of HIV Type III in Patients With AIDS
NCT00002285
A Pilot Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Multicenter Trial to Evaluate the Effect of Ranitidine on Immunologic Indicators in Asymptomatic HIV-1 Infected Subjects With a CD4 Cell Count Between 400-700 Cells/mm3
NCT00002106
A Treatment IND for 566C80 Therapy of Pneumocystis Carinii Pneumonia
NCT00001991
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 8 |
| Phase 2 | 10 |
| Phase 3 | 13 |
| Phase 4 | 4 |
Therapeutic Areas
How the Glaxo Wellcome archive is shaped
65 indexed studies, none listed as recruiting (0% open); 65 completed (100%).
Phase mix: 17 late (III/IV) vs 18 early (I/II) (balanced across stages).
Top condition: HIV Infections (18 trials), 5 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Glaxo Wellcome: archived-pipeline peers nationwide
Peers matched on 65 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Glaxo Wellcome sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 65 archived trials
- BeiGene · 65 trials · 14% recruiting
- LEO Pharma · 65 trials · 5% recruiting
- Neurocrine Biosciences · 65 trials · 18% recruiting
- Women and Infants Hospital of Rhode Island · 65 trials · 22% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Glaxo Wellcome page
65 registered trials is a research-attention snapshot, not an endorsement of Glaxo Wellcome or any single study.
- None of Glaxo Wellcome's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- HIV Infections is the condition Glaxo Wellcome studies most, compare against other sponsors active in the same condition before evaluating a specific study. See HIV Infections trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Glaxo Wellcome pipeline card: 65 registered trials from official public datasets.Report a data error.